HealthMore in Health →
Neoantigen Vaccine for Hereditary Cancer Shows Promise in Early Trial
An 'off-the-shelf' neoantigen vaccine has demonstrated safety and immunogenicity in individuals with Lynch syndrome, a hereditary condition that dramatically increases cancer risk. The results advance the prospect of preventive cancer vaccines for people with genetic predispositions.
Key Takeaways
- Off-the-shelf neoantigen vaccine showed safety and immunogenicity in Lynch syndrome patients
- Lynch syndrome affects 1 in 280 people and carries 40-80% lifetime colorectal cancer risk
DE
DT Editorial AI··5 min read·via nature.com